Production (Stage)
Fate Therapeutics, Inc.
FATE
$1.28
-$0.125-8.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.34M | 13.63M | 13.45M | 12.32M | 6.48M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.34M | 13.63M | 13.45M | 12.32M | 6.48M |
| Cost of Revenue | 115.53M | 118.53M | 117.80M | 117.42M | 123.70M |
| Gross Profit | -102.19M | -104.90M | -104.35M | -105.11M | -117.22M |
| SG&A Expenses | 83.56M | 90.64M | 92.25M | 90.40M | 95.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 199.09M | 209.17M | 210.05M | 207.82M | 219.47M |
| Operating Income | -185.75M | -195.54M | -196.60M | -195.51M | -212.99M |
| Income Before Tax | -175.88M | -186.26M | -178.23M | -175.72M | -190.05M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -175.88 | -186.26 | -178.23 | -175.72 | -190.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -175.88M | -186.26M | -178.23M | -175.72M | -190.05M |
| EBIT | -185.75M | -195.54M | -196.60M | -195.51M | -212.99M |
| EBITDA | -168.28M | -176.58M | -177.57M | -176.34M | -194.08M |
| EPS Basic | -1.49 | -1.65 | -1.65 | -1.71 | -1.92 |
| Normalized Basic EPS | -0.85 | -0.95 | -1.07 | -1.10 | -1.26 |
| EPS Diluted | -1.49 | -1.65 | -1.65 | -1.71 | -1.92 |
| Normalized Diluted EPS | -0.85 | -0.95 | -1.07 | -1.10 | -1.26 |
| Average Basic Shares Outstanding | 471.41M | 454.14M | 434.96M | 415.75M | 396.69M |
| Average Diluted Shares Outstanding | 471.41M | 454.14M | 434.96M | 415.75M | 396.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |